{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:45:39Z","timestamp":1790937939364,"version":"4.1.0"},"reference-count":21,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"unspecified","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"National Institutes of Health\/National Cancer Institute","award":["U10CA180888, U10CA180819, U10CA180821, U10CA180868"],"award-info":[{"award-number":["U10CA180888, U10CA180819, U10CA180821, U10CA180868"]}]},{"name":"National Institutes of Health\/National Cancer Institute","award":["UG1CA233198, UG1CA233320, UG1CA233327"],"award-info":[{"award-number":["UG1CA233198, UG1CA233320, UG1CA233327"]}]},{"DOI":"10.13039\/100001009","name":"Bristol Myers Squibb Foundation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100001009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,1,20]]},"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dual anti-CTLA-4\/PD-1 inhibitors show efficacy in numerous malignancies. We are the first to report on the efficacy of ipilimumab-nivolumab immunotherapy in a dedicated cohort of patients with gynecologic clear cell carcinomas (CCCs), which are rare, aggressive cancers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>DART is a multicenter, multicohort phase II trial of ipilimumab (1\u2009mg\/kg intravenously every 6 weeks) plus nivolumab (240\u2009mg intravenously every 2 weeks), with primary objective as Response Evaluation Criteria in Solid Tumors (RECIST)-based overall response rate (ORR). Secondary objectives were ORR by immune RECIST (iRECIST), progression-free survival (PFS), overall survival (OS), clinical benefit rate (CBR; overall response plus stable disease (SD) \u22656 months), and toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, in this cohort of 32 patients with gynecologic CCC (N=19 ovarian, N=8 endometrial, N=5 cervical; 1\u20138 prior therapies; 3 had prior PD-1 inhibitor exposure), an ORR of 9.38% was seen. This included two complete responses (CRs) (both ovarian origin) that are ongoing at &gt;3 years and one partial response (PR). Overall ORR increased to 12.5% when including one PR by iRECIST criteria for a patient with cervical CCC lasting 26 months, with an OS of 32.0 months. The CBR was 21.88% overall for all 32 (7\/32) evaluable patients with gynecologic CCC. This included two CR, one PR, and two patients with SD &gt;6 months with ovarian CCC and one PR by iRECIST and one SD &gt;6 months in two patients with cervical CCC. PFS for the seven patients with CBR was 63.6+, 47.8+, 40.5+, 50.8+, 7.4, 26, and 58.1+ months. Median OS was 21.7 months for all 32 evaluable patients. Seven of 32 patients (21.9%) discontinued therapy because of toxicity; there were no treatment-related deaths.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Ipilimumab plus nivolumab demonstrated durable antitumor activity in certain patients with CCC of gynecological origin, particularly in those with CCC of ovarian origin. Safety is consistent with the known profile of ipilimumab and nivolumab. Correlative studies to better identify which patients will respond to combined ipilimumab and nivolumab are ongoing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02834013\">NCT02834013<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-012805","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T16:55:48Z","timestamp":1770828948000},"page":"e012805","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["DART\/SWOG\/NCI phase II anti-CTLA-4\/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervix"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct02834013","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1557-7235","authenticated-orcid":false,"given":"Young Kwang","family":"Chae","sequence":"first","affiliation":[{"name":"Northwestern University, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8176-6371","authenticated-orcid":false,"given":"Megan","family":"Othus","sequence":"additional","affiliation":[{"name":"SWOG Statistics and Data Management Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandip P","family":"Patel","sequence":"additional","affiliation":[{"name":"University of California at San Diego Moores Cancer Center, Sacramento, La Jolla, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floortje J","family":"Backes","sequence":"additional","affiliation":[{"name":"Ohio State University, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M","family":"O\u2019Malley","sequence":"additional","affiliation":[{"name":"Ohio State University, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela","family":"Cristea","sequence":"additional","affiliation":[{"name":"City of Hope Comprehensive Cancer Center, Duarte, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4803-8513","authenticated-orcid":false,"given":"Aung","family":"Naing","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Kurnit","sequence":"additional","affiliation":[{"name":"University of Chicago, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramez N","family":"Eskander","sequence":"additional","affiliation":[{"name":"University of California at San Diego Moores Cancer Center, Sacramento, La Jolla, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"T Goodrich","sequence":"additional","affiliation":[{"name":"Parkview Regional Medical Center, Fort Wayne, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R","family":"Robinson","sequence":"additional","affiliation":[{"name":"Tulane University School of Medicine, New Orleans, Louisiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Scalici","sequence":"additional","affiliation":[{"name":"University of South Alabama Mitchell Cancer Institute, South Alabama, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Chan","sequence":"additional","affiliation":[{"name":"California Pacific Medical Center Pacific Campus, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein","family":"Ali-Ahmad","sequence":"additional","affiliation":[{"name":"Michigan CRC NCORP, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Hays","sequence":"additional","affiliation":[{"name":"Ohio State University, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"McCormick","sequence":"additional","affiliation":[{"name":"Legacy Good Samaritan Hospital and Medical Center, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward J","family":"Kim","sequence":"additional","affiliation":[{"name":"University of California Davis, Davis, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanasak","family":"Sueblinvong","sequence":"additional","affiliation":[{"name":"Kaiser Permanente NCORP, Honolulu, Hawaii, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amina","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Rush University Medical Center, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Siedel","sequence":"additional","affiliation":[{"name":"University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Thomes Pepin","sequence":"additional","affiliation":[{"name":"Minnesota Oncology Hematology PA, Woodbury, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin Neal","family":"Bottsford-Miller","sequence":"additional","affiliation":[{"name":"Montana NCORP, Bozeman, Montana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth Olusegun","family":"Fagbemi","sequence":"additional","affiliation":[{"name":"Wisconsin NCORP, Marshfield, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony John","family":"Jaslowski","sequence":"additional","affiliation":[{"name":"Wisconsin NCORP, Marshfield, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Sung","family":"Kim","sequence":"additional","affiliation":[{"name":"Northwestern University, Chicago, Illinois, USA"},{"name":"Temple University Hospital, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liam Il-Young","family":"Chung","sequence":"additional","affiliation":[{"name":"Northwestern University, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Moloney-Lineen","sequence":"additional","affiliation":[{"name":"Northwestern University, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M","family":"McLeod","sequence":"additional","affiliation":[{"name":"SWOG Data Operations Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen X","family":"Chen","sequence":"additional","affiliation":[{"name":"National Cancer Institute, Investigational Drug Branch, Cancer Therapy Evaluation Program, Bethesda, Maryland, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elad","family":"Sharon","sequence":"additional","affiliation":[{"name":"National Cancer Institute, Investigational Drug Branch, Cancer Therapy Evaluation Program, Bethesda, Maryland, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Streicher","sequence":"additional","affiliation":[{"name":"National Cancer Institute, Investigational Drug Branch, Cancer Therapy Evaluation Program, Bethesda, Maryland, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher W","family":"Ryan","sequence":"additional","affiliation":[{"name":"Oregon Health and Science University, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles D","family":"Blanke","sequence":"additional","affiliation":[{"name":"SWOG Group Chair\u2019s Office, Knight Cancer Institute, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razelle","family":"Kurzrock","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin, Milwaukee, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"2026062607451309000_14.2.e012805.1","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ygyno.2009.02.003","article-title":"Management of women with clear cell endometrial cancer","volume":"113","author":"Olawaiye","year":"2009","journal-title":"Gynecol Oncol"},{"key":"2026062607451309000_14.2.e012805.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2015.09.016"},{"key":"2026062607451309000_14.2.e012805.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.04.043"},{"key":"2026062607451309000_14.2.e012805.4","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001863"},{"key":"2026062607451309000_14.2.e012805.5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2008.00747.x"},{"key":"2026062607451309000_14.2.e012805.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2020.100035"},{"key":"2026062607451309000_14.2.e012805.7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01503"},{"key":"2026062607451309000_14.2.e012805.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112435"},{"key":"2026062607451309000_14.2.e012805.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2302312"},{"key":"2026062607451309000_14.2.e012805.10","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2020-001604"},{"key":"2026062607451309000_14.2.e012805.11","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.08.814","article-title":"753P Unlocking the circulating immune landscape of advanced clear-cell ovarian cancer: Insights from the MOCCA trial","volume":"35","author":"Blanc-Durand","year":"2024","journal-title":"Ann Oncol"},{"key":"2026062607451309000_14.2.e012805.12","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1001\/jamaoncol.2024.6797","article-title":"Pembrolizumab in Patients With Advanced Clear Cell Gynecological Cancer: A Phase 2 Nonrandomized Clinical Trial","volume":"11","author":"Kristeleit","year":"2025","journal-title":"JAMA Oncol"},{"key":"2026062607451309000_14.2.e012805.13","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(24)00437-6"},{"key":"2026062607451309000_14.2.e012805.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1008433"},{"key":"2026062607451309000_14.2.e012805.15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0012-z"},{"key":"2026062607451309000_14.2.e012805.16","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1158\/1078-0432.CCR-24-1205","article-title":"Unveiling Commonalities: Exploring Shared Characteristics in Clear-Cell Carcinomas of the Gynecologic Tract","volume":"30","author":"Blanc-Durand","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026062607451309000_14.2.e012805.17","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA5500","article-title":"Final results of BrUOG 354: A randomized phase II trial of nivolumab alone or in combination with ipilimumab for people with ovarian and other extra-renal clear cell carcinomas","volume":"42","author":"Dizon","year":"2024","journal-title":"JCO"},{"key":"2026062607451309000_14.2.e012805.18","doi-asserted-by":"crossref","first-page":"S546","DOI":"10.1016\/j.annonc.2024.08.775","article-title":"713MO Nivolumab and ipilimumab combination treatment in advanced gynaecological clear cell cancers: Results from the phase II MoST-CIRCUIT trial","volume":"35","author":"Klein","year":"2024","journal-title":"Ann Oncol"},{"key":"2026062607451309000_14.2.e012805.19","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.10.406","article-title":"LBA8 Preliminary efficacy of pembrolizumab plus lenvatinib (PL) in recurrent clear cell gynecological cancer (CCGC): Phase II LARA trial (GCGS-OV4\/ APGOT-OV3)","volume":"34","author":"Ngoi","year":"2023","journal-title":"Ann Oncol"},{"key":"2026062607451309000_14.2.e012805.20","doi-asserted-by":"crossref","DOI":"10.1016\/j.gore.2022.101015","article-title":"Mismatch repair deficiency in ovarian cancer","volume":"41","author":"Fuh","year":"2022","journal-title":"Gynecol Oncol Rep"},{"key":"2026062607451309000_14.2.e012805.21","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ygyno.2018.09.001","article-title":"Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management","volume":"151","author":"Oda","year":"2018","journal-title":"Gynecol Oncol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-012805","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T14:45:20Z","timestamp":1782485120000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-012805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":21,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,11]]},"published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1136\/jitc-2025-012805"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-012805","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}